Steroidophobia in dermatology - contemporary problem of the past

Cover Page

Abstract


Topical steroids are the first-line drugs for the treatment of the majority of dermatological diseases. Currently, however, often we have to deal with steroidophobia both among patients and doctors. The problem has been actively studied since steroidophobia can significantly reduce the quality of the treatment. At the same time, with the use of modern topical steroids, such as Advantan, steroidophobia has no grounds due to the high level of safety under normal use of drugs.

E. V. Dvoryankova

Center of Theoretic Problems of Physical and Chemical Pharmacology, Russian Academy of Sciences

Author for correspondence.
Email: dvoriankova@mail.ru

Russian Federation

  1. Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142 (5): 931-936.
  2. Aubert-Wastiaux H., Moret L., Le Rhun A. et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011; 165 (4): 808-814.
  3. Zuberbier T., Orlow S.J., Paller A.S. et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 226-232.
  4. Rathi S.K., D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 2012; 57 (4): 251-259.
  5. Rathi S. Abuse of topical steroid as cosmetic cream: A social background of steroid dermatitis. Indian J Dermatol 2006; 51: 154-155.
  6. Bhat Y.J., Manzoor S., Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol 2011; 56: 30-32.
  7. Moret L., Anthoine E., Aubert-Wastiaux H. et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One 2013; 8 (10): e76493.
  8. Huang K.E., Davis S.A., Cantrell J., Feldman S.R. Increasing use of non-traditional vehicles for psoriasis and other inflammatory skin conditions. Dermatol Online J 2014; 20 (9): 10.
  9. Belousova T.A. Naruzhnaya terapiya allergicheskogo dermatita i ekzemy. Vestn dermatol venerol 2008; 2: 97-103. [Белоусова Т.А. Наружная терапия аллергического дерматита и экземы. Вестн дерматол венерол 2008; 2: 97-103.]
  10. Perlamutrov Yu.N., Ol'khovskaya K.B., Samtsov A.V. Results of an all-russian multicenter open-label follow-up study «ELLIPS» to evaluate the efficacy, safety and tolerance of treatment with various Forms of Advantan in eczema patients. Vestn Dermatol Venerol 2009; 6: 116-123. [Перламутров Ю.Н., Ольховская К.Б., Самцов А.В. и соавт. Результаты Всероссийского многоцентрового открытого наблюдательного исследования «ЭЛЛИПС» по определению эффективности, безопасности и переносимости лечения больных экземой различными формами препарата Адвантан. Вестн дерматол венерол 2009; 6: 116-123.]
  11. Fritsch P. Clinical experience with methylprednisolone aceponate (MPA) in eczema. J Dermatol Treat 1992; 3 (2): 17-19.
  12. Kecskes A., Heger-Mahn D., Kleine-Kuhlmann R. et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol 1993; 29: 576-580.
  13. Zaumseil R.-P., Kecskes A., Tauber U. et al. Methylprednisolone aceponate (MPA) - a new therapeutic for eczema: a pharmacological overview. J Dermatol Treat 1992; 3 (Suppl 2): 3-7.
  14. Klinicheskaya allergologiya detskogo vozrasta s neotlozhnymi sostoyaniyami. Rukovodstvo dlya vrachey pod redaktsiey Balabolkina I.I., Bulgakovoy A.V. M: MIA 201; 264. [Клиническая аллергология детского возраста с неотложными состояниями. Руководство для врачей под редакцией И.И. Балаболкина, А.В. Булгаковой. М: МИА 2011; 264.]

Views

Abstract - 99

PDF (Russian) - 53

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies